Rezolute Highlights 75% IV Dextrose Discontinuation and SunRIZE Phase 3 Results
RZLT•Rezolute highlighted four presentations at the Endocrine Society including meta-analyses of congenital hyperinsulinism complications and health-economic burdens, and case series showing 75% of nine tumor HI patients discontinued IV dextrose/TPN under the Expanded Access Program. SunRIZE Phase 3 data reaffirmed ersodetug’s therapeutic benefit in congenital HI.
1. ENDO Meeting Data Highlights
Rezolute delivered four presentations at the Annual Meeting of the Endocrine Society covering systematic analyses of congenital hyperinsulinism natural history, adverse neurologic outcomes, and health-economic burdens using meta-analysis and claims data. These findings aim to quantify disease impact and support future health economics research for ersodetug’s development.
2. Tumor HI Expanded Access Results
A case series of nine tumor hyperinsulinism patients in the Expanded Access Program showed that 75% achieved complete discontinuation of IV dextrose and total parenteral nutrition, demonstrating ersodetug’s potential to manage refractory hypoglycemia in malignant insulinoma and non-islet cell tumor HI cases.
3. Review of Phase 3 Programs
An oral presentation reviewed sunRIZE Phase 3 congenital HI results, underscoring ersodetug’s meaningful therapeutic benefit in reducing hypoglycemia events. Company executives also cited interim upLIFT Phase 3 study observations in tumor HI patients, indicating consistent benefit across both congenital and acquired hyperinsulinism indications.
